News | Cardiac Imaging | October 11, 2022

Identifying Patients with Sarcoidosis at Risk for Bad Cardiac Outcomes

Researchers from the University of Minnesota Medical School found that patients with certain features on magnetic resonance imaging (MRI) of the heart are at much higher risk for cardiac sarcoidosis-related adverse outcomes.

Chetan Shenoy, MBBS, MS


October 11, 2022 — Researchers from the University of Minnesota Medical School found that patients with certain features on magnetic resonance imaging (MRI) of the heart are at much higher risk for cardiac sarcoidosis-related adverse outcomes. These patients may benefit from an implantable cardioverter defibrillator. Meanwhile, other features identified patients at very low risk who might not benefit from the device. These findings were published recently in JAMA Cardiology. 

Cardiac sarcoidosis is a rare inflammatory heart disease that can result in rhythm disturbances and heart failure. Sarcoidosis is estimated to affect approximately 200,000 Americans.  

“Late gadolinium enhancement on cardiovascular magnetic resonance imaging is often used to diagnose cardiac sarcoidosis. Our research shows that not all patients with late gadolinium enhancement on cardiac MRI  have the same risk of adverse outcomes, particularly ventricular arrhythmias,” said Chetan Shenoy, MBBS, MS, an associate professor of medicine at the University of Minnesota Medical School and the lead author of the study. “We believe our findings will help optimize the clinical care of patients with suspected cardiac sarcoidosis, and consequently, lead to better outcomes.” 

In this largest study yet of suspected cardiac sarcoidosis investigated by cardiac MRI, the researchers studied 504 patients. The MRI features were based on the research team’s previously published study that described features of cardiac damage in the hearts of patients with cardiac sarcoidosis who had suddenly died or needed heart transplantation. 

Researchers note that these findings should be replicated in other, more diverse, cohorts. Whether clinical management guided by these cardiac MRI features improves outcomes in patients with suspected cardiac sarcoidosis should be prospectively tested in a randomized trial. 

For more information: www.med.umn.edu 

Related Cardiac Sarcoidosis Content: 

VIDEO: Utilization of PET For Evaluation of Cardiac Sarcoidosis 

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis 

New PET-CT Scan Improves Detection in Rare Cardiac Condition 

25 Most Impactful Nuclear Cardiology Articles 

Recent Advances in Cardiac Nuclear Imaging Technology 


Additional Content

News | Heart Failure

Oct. 14, 2026 — GLP-1 weight loss drugs known may help protect against heart failure even at doses too low to produce ...

Home October 19, 2026
Home
Feature | Heart Failure | Kyle Hardner

The shift toward steering appropriate cardiovascular cases to outpatient settings is gaining momentum, driven by a ...

Home September 11, 2026
Home
News | Heart Failure

Sept. 9, 2026— Atman Health has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to develop an ...

Home September 11, 2026
Home
News | Heart Failure

Aug. 31, 2026 — A new heart failure (HF) treatment effect calculator could help overcome one of the largest barriers to ...

Home August 31, 2026
Home
News | Heart Failure

July 28, 2026 — Abbott has initiated the Treat TR study, a post-market study of the company’s TriClip transcatheter edge ...

Home July 29, 2026
Home
Subscribe Now